Orforglipron (Foundayo) introduces a new oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken without food ...
Peters attributed BAQSIMI performance to net price: “BAQSIMI's revenues decreased 15% to $32.4 million... as a result of lower average selling prices,” while units rose “8%,” and he said the lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results